Experienced in HNRNPH2-Related Disorder

Dr. Sonia Partap

Pediatric Neurology | Pediatrics | Neurology
725 Welch Rd, 
Palo Alto, CA 
Experienced in HNRNPH2-Related Disorder
725 Welch Rd, 
Palo Alto, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sonia Partap is a Pediatric Neurologist and a Pediatrics provider in Palo Alto, California. Dr. Partap is rated as an Experienced provider by MediFind in the treatment of HNRNPH2-Related Disorder. Her top areas of expertise are Medulloblastoma, Glioma, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Tumor.

Her clinical research consists of co-authoring 68 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Neurology
Pediatrics
Neurology
Licenses
Pediatrics in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
View 4 Less Insurance Carriers -

Locations

725 Welch Rd, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Partap has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine
Study Phase: Phase 2
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: April 27, 2025
Intervention Type: Biological
Study Drugs: TTRNA-xALT, TTRNA-DCs
Study Phase: Phase 2
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Alisertib, Methotrexate, Cisplatin, Carboplatin, Cyclophosphamide, Etoposide, Topotecan, Vincristine
Study Phase: Phase 2
View 4 Less Clinical Trials

68 Total Publications

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
Journal: Neuro-oncology
Published: April 17, 2025
Similar Doctors
Advanced in HNRNPH2-Related Disorder
Dr. Candida M. Brown
Pediatrics | Pediatric Neurology
Advanced in HNRNPH2-Related Disorder
Dr. Candida M. Brown
Pediatrics | Pediatric Neurology
400 Taylor Blvd, Suite 306, 
Pleasant Hill, CA 
 (36.8 miles away)
925-691-9688
Languages Spoken:
English
See accepted insurances

Candida Brown is a Pediatrics specialist and a Pediatric Neurologist in Pleasant Hill, California. Dr. Brown is rated as an Advanced provider by MediFind in the treatment of HNRNPH2-Related Disorder. Her top areas of expertise are Autism Spectrum Disorder, Increased Head Circumference, Aphantasia, and HNRNPH2-Related Disorder.

Experienced in HNRNPH2-Related Disorder
Dr. Susy S. Jeng
Pediatric Neurology | Pediatrics | Neurology
Experienced in HNRNPH2-Related Disorder
Dr. Susy S. Jeng
Pediatric Neurology | Pediatrics | Neurology
725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Susy Jeng is a Pediatric Neurologist and a Pediatrics provider in Palo Alto, California. Dr. Jeng is rated as an Advanced provider by MediFind in the treatment of HNRNPH2-Related Disorder. Her top areas of expertise are Zika Virus Disease, Microcephaly with Spastic Quadriplegia, Microcephaly, and Migraine.

Experienced in HNRNPH2-Related Disorder
Dr. Christopher Lee
Pediatric Neurology | Neurology
Experienced in HNRNPH2-Related Disorder
Dr. Christopher Lee
Pediatric Neurology | Neurology
725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Christopher Lee is a Pediatric Neurologist and a Neurologist in Palo Alto, California. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of HNRNPH2-Related Disorder. His top areas of expertise are Seizures, Generalized Tonic-Clonic Seizure, Memory Loss, and Lennox-Gastaut Syndrome (LGS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Partap's expertise for a condition
ConditionClose
View All 20 Advanced Conditions
View All 158 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile